Novo Nordisk Rises, GoodRX Surges, CVS Gains on UBS Upgrade

On this episode of Stock Movers:
- Novo Nordisk (NVO) shares rise after news that it's slashing the cost of Ozempic for cash-paying patients to $499 a month through NovoCare and partnering with GoodRx Holdings Inc. to offer it at the same price at US pharmacies.
- GoodRX (GDRX) shares surge on news Novo Nordisk is slashing the cost of Ozempic and partnering with GoodRx to offer it at US pharmacies.
- CVS (CVS) shares gain after UBS upgraded the drugstore chain to buy from neutral. Analyst Kevin Caliendo writes that the upgrade follows “two strong consecutive quarters of execution and early signs that the Healthcare Benefits (HCB) segment fixes are on track.”

See omnystudio.com/listener for privacy information.